By G HossainPosted on August 24, 2026Posted in Pharmaceutical & Bio Science, UncategorizedTagged bio science career, blogs, business career news, career tips, job blog, job news, RJF Pharmaceutical Jobs Not much is known about Boehringer Ingelheim’s drug candidate, dubbed BI 3031185, though the asset has completed at least two other Phase 1 studies this year. Boehringer Ingelheim suspends early study for pill candidate after ‘safety event’ Post navigation Sax Wealth Advisors adds Florida wealth managerRoche bets up to $2.3B in Hanmi pact for next-gen weight loss drug